Company Name Afferent Pharmaceuticals
Mailing Address 2755 Campus Drive San Mateo, CA 94403 USA
Company Description A leader in the development of novel, selective small molecules that target the P2X3 purinergic receptor, for the treatment of a range of debilitating symptoms and sensory disorders.
M&A Terms Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of Afferent in exchange for an upfront payment of $500 million in cash. Also, Afferent shareholders will be eligible to receive a total of up to an additional $750 million associated with the attainment of certain clinical development and commercial milestones for multiple indications and candidates, including AF-219